BridgeBio Pharma, Inc.
BBIONext catalyst
BBP-418
Limb-girdle muscular dystrophy type 2I/R9
Get an email about BBIO's next catalysts
Track BridgeBio Pharma (BBIO) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 2 more upcoming events in our data (PDUFA date).See the timeline
3 upcoming, 1 past
FDA PDUFA Date BBP-418
For Limb-girdle muscular dystrophy type 2I/R9. NDA, Priority Review. Verified against the company announcement on 2026-10-16.
SourceFDA PDUFA Date Infigratinib (priority)
For children with achondroplasia. nda filing. Extracted from SEC filing: EXHIBIT 99.1
SourceFDA PDUFA Date encaleret (standard)
For autosomal dominant hypocalcemia type 1 (ADH1). NDA filing. Extracted from SEC filing: EXHIBIT 99.1
SourceUpcoming FDA decisions
Market Overview
Stock performance and key metrics
Acoramidis
Amyloidosis
Encaleret
Autosomal Dominant Hypocalcemia (ADH)
Infigratinib
Achondroplasia
AG10
Familial ATTR-CM (ATTRm-CM, or FAC)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Acoramidis | Phase 3 | Amyloidosis | - | - |
Encaleret | Phase 3 | Autosomal Dominant Hypocalcemia (ADH) | - | - |
Infigratinib | Phase 3 | Achondroplasia | - | - |
AG10 | Phase 2 | Familial ATTR-CM (ATTRm-CM, or FAC) | - | - |
Frequently asked questions
What is in BridgeBio Pharma, Inc.'s drug pipeline?β
CatalystAlert tracks 4 drug candidates in BridgeBio Pharma, Inc.'s (BBIO) pipeline across Phase 3, Phase 2. Its lead program is Infigratinib (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is BridgeBio Pharma, Inc.'s next FDA catalyst?β
BridgeBio Pharma, Inc.'s (BBIO) next tracked catalyst is a PDUFA date expected Nov 27, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track BBIO biotech catalysts?β
Add BBIO to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow BridgeBio Pharma, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page β sourced from ClinicalTrials.gov, FDA and SEC filings.
